United States: Amarin Case Demonstrates Limits Of ITC Jurisdiction

In what represents a departure from typical U.S. International Trade Commission (ITC) practice, the ITC on Oct. 27, 2017, declined to institute a Section 337 investigation based on a complaint brought by Amarin Pharma Inc. and Amarin Pharmaceuticals Ireland Ltd. ("Amarin"). The commission's non-institution decision (as well as a brief concurring memorandum from Commissioner Meredith Broadbent) provides incremental insight into the question of the ITC's jurisdiction and deference to sister government agencies.

Background

Section 337 broadly authorizes the ITC to investigate all forms of "[u]nfair methods of competition and unfair acts in the importation of articles." This breadth of authority makes the ITC a potentially attractive forum for companies seeking creative solutions to defend their rights and gain a competitive edge in global business disputes, especially given that the ITC's authority to investigate such claims "is broad enough to prevent every type and form of unfair practice ... ."1 For example, based on that broad authority, the ITC has instituted investigations in recent years under Section 337(a)(1)(A) based in whole or in part on allegations of trade secret misappropriation, common law trademark and trade dress infringement, breach of contract, tortious interference with contractual relations, false advertising under the Lanham Act and violation of a state law deceptive trade practice prohibitions.

Amarin filed its complaint with the ITC on Aug. 30, alleging that certain synthetically produced omega-3 products — specifically, synthetically produced eicosapentaenoic acid (EPA) omega-3 products in ethyl ester or reesterified triglyceride form — were unlawfully labeled and marketed as "dietary supplements" in violation of Section 337, the Lanham Act and the Food, Drug and Cosmetic Act (FDCA).2 Amarin alleged that, based on the standards and definitions in the FDCA, these products are not "dietary supplements," but instead are actually unapproved "new drugs" that require approval from the U.S. Food and Drug Administration (FDA) (as well as pre-approval testing) and cannot lawfully be marketed and sold as dietary supplements.3 Amarin named a variety of domestic and foreign entities as proposed respondents, and requested that the ITC institute a Section 337 investigation and issue a general exclusion order barring the importation into the United States by any entity of synthetically produced omega-3 products.4

Amarin's complaint drew significant interest from the proposed respondents and other members of the public, as well as from industry press. In addition to proposed respondents DSM Nutritional Products, Pharmavite and Nordic Naturals, several other entities initially submitted comments to the ITC requesting that the ITC decline to institute the investigation on public interest grounds, including the Council for Responsible Nutrition, the Global Organization for EPA and DHA Omega, the Consumer Healthcare Products Association and Hale Oswick Family and Friends.

Amarin and several of the proposed respondents engaged in an unusual exchange of pre-institution briefing on the issue of whether the ITC appropriately had jurisdiction over Amarin's claims — with the proposed respondents arguing that the FDA, not the ITC, should be the agency to determine the propriety of complained-of conduct. Amarin relied in part on the Supreme Court's decision in POM Wonderful LLC v. Coca-Cola Co., 134 S. Ct. 2228 (2014), which held that the FDCA does not preclude a private party from bringing a Lanham Act claim challenging a misleading food label that is regulated under the FDCA. Although that case dealt with food labels, rather than purported "new drugs," Amarin argued that the analysis should be the same. In their response, the proposed respondents argued in part that Amarin's claims were improper because the FDA is exclusively tasked with administration of the FDCA and has not made a determination as to whether the accused products are properly labeled as drugs or dietary supplements.

More specifically, the proposed respondents argued that resolving the fundamental issue in Amarin's case — whether the accused products are in fact "dietary supplements" or "new drugs" — would, require the ITC to interpret and apply the FDCA, alleging this is solely within the FDA's jurisdiction. Many of the proposed respondents and third parties also relied on the ITC's 2012 decision not to institute a complaint brought by K-V Pharmaceutical Company in Certain Hydroxyprogesterone Caproate and Products Containing the Same, Docket No. 2919, where the ITC declined to investigate claims brought under the FDCA.5

On Oct. 6, the FDA itself weighed in, filing its own request asking the ITC not to institute an investigation into Amarin's complaint. The FDA claimed that Amarin was attempting an unlawful private FDCA enforcement action, and that the FDCA precludes claims that would require any entity other than the FDA to interpret provisions of the FDCA. The FDA echoed the proposed respondent's arguments, stating that it had not yet made a decision on whether the synthetically produced omega-3 products were "dietary supplements" or "new drugs" under the FDCA, and that it was in the process of drafting guidance for the industry. As such, the FDA requested that the ITC decline to institute under principles of interagency comity.

Given the voluminous submissions from the parties and the public and the unique issues posed by Amarin's complaint, the ITC twice delayed its decision on whether to institute the complaint, deliberating for nearly an additional month before finally issuing its decision on Oct. 27.

The ITC's Non-Institution Decision

The ITC's governing statute, 19 U.S.C. § 1337, provides in part that the ITC "shall investigate any alleged violation of this section on complaint under oath." 19 U.S.C.§ 1337(b). Nonetheless, the ITC here found that "Amarin's complaint does not allege an unfair method of competition or an unfair act" as required by the statute and the commission's rules. Specifically, the ITC determined that the Lanham Act allegations in this case were precluded by the FDCA, and noted that the FDA is the entity charged with the administration of the FDCA. As such, the ITC declined to institute an investigation and dismissed the complaint.

One commissioner, Commissioner Meredith Broadbent, issued a brief memorandum concurring with the ITC's non-institution decision, agreeing that Amarin's complaint failed to properly allege an unfair method of competition or an unfair act under Section 337. However, she left the door open for future complaints, stating that she did not reach the issue of whether properly pleaded claims based on the FDCA may be cognizable under Section 337. (It is worth noting Commissioner Broadbent, along with then-Commissioner Dean Pinkert, issued a similar concurring memorandum in Hydroxyprogesterone Caproate in 2012.)

What's Next for Amarin?

In the short term, Amarin could potentially petition the commission to reconsider its dismissal of the complaint. Furthermore, given that the ITC's governing statute directs that the ITC "shall investigate" alleged violations of Section 337, it's possible that Amarin might seek to challenge that ITC's non-institution as an arbitrary and capricious act in violation of the Administrative Procedures Act (APA) — either in an appeal to the Federal Circuit or in a collateral district court action. (In fact, Amarin hinted in some of its briefing that it would consider a denial of institution to be a potential APA violation.) While on-point precedent is sparse, Amarin likely cannot directly appeal the commission's non-institution decision, because Section 337 provides that only a final determination of the commission may be appealed. In the past, the Federal Circuit has exercised jurisdiction over an appeal from a decision by the ITC where that decision had equivalent effect of a final determination on the merits.6 Yet it's possible Amarin may seek a writ of mandamus from the Federal Circuit, arguing that the commission's decision not to institute the investigation was arbitrary and capricious in violation of the APA,7 especially given Section 337's mandate that the commission shall investigate any properly pled Section 337 complaints.

In the non-ITC context, Amarin could also file a citizen petition pursuant to 21 C.F.R. § 10.30, and request that the FDA issue a new regulation classifying the accused omega-3 products as "new drugs." Doing so would allow Amarin to present all of its arguments that it made before the commission to the FDA instead. (The FDA must respond to (but not necessarily issue a final ruling on) all citizen petitions within 180 days.)8

What's Next for Others?

In the long term, and for those who have been watching this case with interest, the ITC's decision provides incremental guidance regarding the types of nonpatent claims that may (or may not) give rise to a Section 337 investigation, especially in the FDCA context. The ITC's position here and in Hydroxyprogesterone Caproate seems to be one of deference to the FDA on issues that are unique to the FDA's enforcement authority — i.e., where a theory of a violation of Section 337 would require the ITC to interpret the FDCA in an area where the FDA has not yet provided guidance, the ITC appears likely to decline to institute. However, where the FDA has already made a determination and the ITC can simply apply that determination to resolve Lanham Act claims without needing to resolve questions that require the FDA's (or another agency's) special expertise, the ITC may be more receptive to institution.

Indeed, the ITC previously instituted an investigation in Certain Potassium Chloride Powder Products, Inv. No. 337-TA-1013 (Potassium Chloride) over similar objections to those raised in Amarin's case. In Potassium Chloride, the complainants alleged that the respondents falsely and deceptively marketed their drugs as FDA-approved in violation of the Lanham Act and the FDCA, when in fact the complainants had the only FDA-approved drug of that type on the market.9 In response, the Potassium Chloride respondents argued that the ITC should not institute an investigation because doing so would "usurp the exclusive regulatory power of FDA" and "encroach on the FDA's authority under the FDCA."10 Nonetheless, the ITC determined that institution was proper in that case. Notably, unlike the accused omega-3 products in Amarin's case, the accused drugs in Potassium Chloride were unquestionably drugs under the FDCA and were not approved by the FDA, and so the ITC did not need to resolve any questions that required the FDA's expertise before reaching the merits of the Lanham Act arguments.

Similarly, in Certain Light Emitting Diode Products and Components Thereof, Inv. No. 337-TA-947, after the respondents were accused of violating Section 337 and the Lanham Act by falsely marking inferior LED lightbulbs with the ENERGY STAR® label, the respondents argued that the ITC did not have jurisdiction to resolve their alleged Lanham Act violations because another agency, this time the EPA, had exclusive regulatory authority over the use of that label. The administrative law judge (ALJ) in that case rejected that argument, stating "[the ITC] has frequently exercised its authority with respect to Lanham Act violations based on the failure to meet and follow requirements set by other federal agencies."11 Therefore, as the ALJ in Certain Light Emitting Diode Products further explained, the ITC has jurisdiction over Lanham Acts claims where those "claims do not require the [ITC] 'to interpret complex regulations, resolve technical issues or engage in policy judgments that require the expertise of [another agency].'"12

It still remains to be seen whether it is possible to bring a Section 337 claim based at least in part on the FDCA. However, at least one commissioner may be open to the assertion of such claims, as long as they are properly pled. Going forward, those seeking to invoke the ITC's broad unfairness authority will likely take care to bring only those Lanham Act claims that would not require the ITC to "step on the FDCA's toes."13

This article by counsel Matthew Rizzolo and associate Vladimir Semendyai was published by Law360 on November 22, 2017.

Footnotes

1 Certain Air Impact Wrenches Inv. No. 337-TA-311, 1991 WL 788551, at *7 (May 6, 1991) (quoting Senate Finance Committee Report, S. Rep. No. 67-595, at 3 (1922)).

2 Complaint at ¶¶ 1, 58–60, Certain Synthetically Produced, Predominantly EPA Omega-3 Prods.in Ethyl Ester or Re-esterified Triglyceride Form, Docket No. 3247 (Aug. 30, 2017).

3 Id. at ¶¶ 84–101, 106–113.

4 Id. at 103–04, ¶¶ 24–31.

5 See Certain Hydroxyprogesterone Caproate and Prods. Containing the Same, Docket No. 2919, Order (Dec. 21, 2012).

6 See Amgen Inc. v. ITC, 902 F.2d 1532, 1535 (Fed. Cir. 1990); see also Import Motors Ltd. v. ITC, 530 F.2d 940, 944 (C.C.P.A.1976) (exercising jurisdiction over an appeal from the ITC where the commission's decision had the "effect upon appellants [that] is the equivalent of a final determination.").

7 See, e.g., Syntex Agribusiness Inc. v. ITC, 659 F.2d 1038, 1039, 1041 (C.C.P.A. 1981) (denying petition for writ of mandamus to compel ITC to institute an investigation).

8 See 21 C.F.R. § 10.30(e)(2).

9 See Complaint at ¶¶ 24–56, Certain Potassium Chloride Powder Prods., Inv. No. 337-TA-1013 (June 15, 2016).

10 See respondents' Comments Relating to the Public Interest at 2–4, Certain Potassium Chloride Powder Prods., Inv. No. 337-TA-1013 (July 7, 2016).

11 Certain Light Emitting Diode Prods. and Components Thereof, Inv. No. 337-TA-947, Initial Determination at 425 (Sept. 2, 2016).

12 Id. at 426 (quoting Netgear Inc. v. ASUSTek Comput. Inc., 2013 WL 6512700 (N.D. Cal. Dec. 12, 2013)).

13 Hi-Tech Pharms. Inc. v. Hodges Consulting Inc., 230 F. Supp. 3d 1323, 1331 (N.D. Ga. 2016).

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions